Sign inCreate account

Report workspace tools

NCT04338529COMPLETEDanonymous

Alendronate in an Weekly Effervescent Tablet Formulation for Preservation of Bone Mass After Denosumab Discontinuation in Postmenopausal Women with Low Bone Mass. an Observational Study (Binosto After Denosumab - the BAD Study)

Sponsor

Source record

251 Hellenic Air Force & VA General Hospital

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Postmenopausal Osteoporosis

Indication / condition

AI-normalized

Postmenopausal Osteoporosis

Intervention

Source record

Binosto 70Mg Effervescent Tablet

Source & freshness

Source record

NCT ID

NCT04338529

Original source

ClinicalTrials.gov

Source last updated

Dec 02, 2024

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04338529

Title

Alendronate in an Weekly Effervescent Tablet Formulation for Preservation of Bone Mass After Denosumab Discontinuation in Postmenopausal Women with Low Bone Mass. an Observational Study (Binosto After Denosumab - the BAD Study)

Sponsor

251 Hellenic Air Force & VA General Hospital

Status

COMPLETED

Phase

Observational

Condition raw

Postmenopausal Osteoporosis

Condition normalized

Postmenopausal Osteoporosis

Modality raw

Postmenopausal Osteoporosis

Modality normalized

monoclonal antibody

Target raw

Postmenopausal Osteoporosis

Target normalized

Postmenopausal Osteoporosis

Interventions

Binosto 70Mg Effervescent Tablet

Public preview

Source record

This study investigates the efficacy of transitioning from denosumab to oral alendronate in a weekly effervescent tablet formulation for preserving bone mineral density (BMD) in postmenopausal women with low bone mass. The study aims to provide insights into optimal treatment duration and management strategies following denosumab discontinuation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Alendronate in an Weekly Effervescent Tablet Formulation for Preservation of Bone Mass After Denosumab Discontinuation in Postmenopausal Women with Low Bone Mass. an Observational Study (Binosto After Denosumab - the BAD Study)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04338529

Status

COMPLETED

Phase

Observational

Sponsor

251 Hellenic Air Force & VA General Hospital

Executive brief

Investment-Ready Snapshot

This study investigates the efficacy of transitioning from denosumab to oral alendronate in a weekly effervescent tablet formulation for preserving bone mineral density (BMD) in postmenopausal women with low bone mass. The study aims to provide insights into optimal treatment duration and management strategies following denosumab discontinuation.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 02, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04338529

Indication

Postmenopausal Osteoporosis

Modality

monoclonal antibody

Target

Postmenopausal Osteoporosis

Intervention

Binosto 70Mg Effervescent Tablet

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.